Cancer Screening

Exposure to the colorless, odorless gas called radon is the second leading cause of lung cancer in the U.S. and the leading cause of lung cancer among nonsmokers, according to the American Cancer Society.

Cancer screening recommendations for patients with autoimmune diseases largely rely on clinical experience and extrapolation in the absence of abundant data, according to a speaker at the 2021 Congress of Clinical Rheumatology-East meeting.

Many women skipped important preventive health care appointments in 2020 due to the COVID-19 pandemic, especially if they were from lower-income and minority communities, according to a study published in JAMA Health Forum.

This week, CHEST issues guidelines for low-dose CT screening for lung cancer; severe COVID-19 survivors experience pulmonary impairment; the FDA approves Prograf to prevent lung transplant rejection; and more.

More than 1 in 4 men aged 55 to 69 years and 1 in 3 men aged 70 years and older underwent prostate cancer screening in the previous 12 months, “suggesting potential overuse among some men,” researchers reported.

Many transgender men and nonbinary people assigned female at birth, or TMNB, reported barriers to cervical cancer screening, according to results of a cross-sectional survey of these underserved populations.

Transvaginal ultrasound used to determine appropriateness of endometrial cancer biopsy missed nearly five times more cases of the disease among Black women vs. white women, according to a simulated cohort study published in JAMA Oncology.

The American College of Chest Physicians released a new guideline and expert panel report that contains recommendations and updates the evidence base for the benefits, harms and implementation of low-dose CT screening for lung cancer.

Multitarget fecal immunochemical testing yielded better diagnostic accuracy in the detection of advanced adenomas compared with basic FIT, according to research published in Annals of Internal Medicine.

Combining an MRI-targeted biopsy approach with the Stockholm3 blood test for prostate cancer screening reduced overdetection while still identifying significant cancer, according to results of the randomized, population-based STHLM3MRI trial.